Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
| 対象疾患 | Human Immunodeficiency Virus, HBV, Fibrosis, Liver, Cirrhosis, Liver |
|---|---|
| 相 | 該当なし |
| スポンサー | University of Alabama at Birmingham |
| ステータス | 完了 |
| 参加者数 | 349 名 |
| 介入（薬剤） | Anti-HIV Agents |
| 開始日 | 2015年10月 |
| 完了日 | 2026年5月28日 |
| 結果公開日 | 2026年7月2日 |
概要
A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to identify the risk factors for major endpoints of interest, including HCC and HBV functional cure. This cohort will also create a pool of potential participants for in-depth mechanistic studies and clinical trials of novel HBV cure drugs.
Reduction in Liver Fibrosis Stage
| HBV/HIV Cohort | 46 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)